Coherus Oncology (CHRS) Non-Current Deferred Tax Liability (2023 - 2026)

Coherus Oncology has disclosed Non-Current Deferred Tax Liability across 4 years of filings, most recently posting $1.1 million for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $1.1 million (changed 0.0% YoY), while the FY2025 annual figure was $1.1 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability came in at $1.1 million for Q2 2026 at Coherus Oncology, roughly flat from $1.1 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q3 2023 to a low of $1.1 million in Q3 2023.
• Average Non-Current Deferred Tax Liability over 4 years is $1.1 million, with a median of $1.1 million recorded in 2023.
• The largest YoY upside for Non-Current Deferred Tax Liability was 0.0% in 2024 against a maximum downside of 0.0% in 2024.
• Over 4 years, Non-Current Deferred Tax Liability stood at $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $1.1 million in Q2 2026, $1.1 million in Q1 2026, and $1.1 million in Q4 2025.